Introduction {#s1}
============

The eye presents the perfect organ for gene therapy. It is an immune privileged site, which is protected by the blood retinal barrier. The target cells, such as photoreceptors and retinal pigment epithelium are frequently non-dividing, meaning any intervention is likely to last for life. The different structures in the eye can be visualized due to the optical clarity inherent in the eyeball or can be imaged with well-documented techniques ([@B47]; [@B17]). The structures in the eye can be targeted by various surgical procedures. Finally, many disease processes have a degree of symmetry. This means that, when treating one eye, the other eye can act as a control for comparison. For these reasons, ocular gene therapy is being trialed as an experimental treatment for an increasing number of conditions. There are established techniques to measure both structural and functional changes, with work ongoing in this field to evaluate the different diseases being treated. The success of gene therapy can be determined by the pattern of change seen in visual function measurement. Since visual function is the major marker for success of gene therapy, it is critical to establish guidelines for best practice.

Gene therapy can follow several different strategies. Most commonly, it is the supplementation of a defective gene with a working copy in affected target cells, as happens in achromatopsia and choroideremia. However, in some cases, such as with neovascular age-related macular degeneration, the gene expression may introduce a factor to help dampen the disease response. The mode of action is less important than the disease being investigated in determining the appropriate measures to use for trial monitoring. The Monaciano Symposium identified the measurement of treatment outcome as an area requiring priority review in order to aid the robustness of clinical interventional trials ([@B43]). It calls for the investigation into appropriate outcome measures for each disease to measure structure and function without adding an unreasonable burden on the patient. They propose a standardization of testing protocols and data analysis. The reproducibility and reliability of tests should also be pre-defined.

With the increase in the number of trials using ocular gene therapy, the importance of adequate outcome measures is gathering interest. The success of gene therapy relies on three key aspects. The viral vector is developed over several years and optimized in animal models before reaching human trials ([@B28]; [@B37]). Much work has been conducted on optimizing the delivery of the therapeutic vector ([@B41]; [@B46]). Another component required for success of clinical trials is the adequate measurement of therapeutic impact. This requires a combination of the evaluation of ocular structure *via* imaging, and measurement of visual function. Standardized clinical visual function measures were largely developed for use in a clinical setting rather than for the assessment of novel interventions and may not always be adequate for measurement of a therapeutic effect. For example, the 100-hue test for color vision has wide normative ranges, making interpretation of longitudinal data difficult ([@B26]). The relationship of the outcome measures to disease progression, and therefore, the therapeutic window should also be better understood to interpret clinical trial findings. In addition, disease features such as visual field loss may make the conduct the test difficult.

A systematic review of gene therapy for retinal disease has been registered on the PROSPERO database (CRD42017056500) by London City University, but not yet completed. This specifies visual outcome as the outcome measure for assessing the success of trials, but the type of vision measure being looked at is not detailed, demonstrating the importance of providing further guidance on this topic. Additionally, as bilateral gene therapy will become more common, there will no longer be a control eye to provide a comparison as is done in many phase 1 trials, making vision outcome even more critical ([@B31]). Visual function is a combination of many aspects of vision, including detail, color, contrast, speed of vision, and night vision. The objective of this paper is to review the outcome measures listed and published for registered gene therapy trials in order to establish current practice, and to consider the scope for development of relevant outcome measures.

Method {#s2}
======

All clinical interventional trials must be registered on a publically available database. The databases on Clinicaltrials.gov ([RRID: SCR_002309](https://scicrunch.org/resolver/RRID:SCR_002309)), EU clinical trials register ([RRID SCR_005956](https://scicrunch.org/resolver/RRID:SCR_005956)), and the NIH clinical trials register were searched for all registrations by the end of October 2018, using the following search terms: gene therapy, subretinal injection, intravitreal injection, STX eye trial, Nightstar, Applied genetic, MeiraGTx, Hemera, Oxford Biomedica, Sanofi, Spark, ProQR, GenSight, and Genzyme.

Duplicate records were omitted from analysis. Natural history studies or studies specifically for long-term follow up of patients in a previous trial were also excluded in order to focus on the primary interventional trials. We then searched for any results from studies with a registered start date of greater than 12 months before October 2018. This was done *via* PubMed, study group websites, and Scopus. Searches were conducted using the investigator details and registered study name. Publications for the same study were grouped together and analyzed as an integrated dataset, with discrepancies between the primary outcome measure on the clinical trials record *versus* the final publications being noted.

Results {#s3}
=======

Listed Outcome Measures {#s3_1}
-----------------------

We identified 50 unique clinical trials on the registers for 17 ophthalmic indications ([**Supplementary Figure**](#SM1){ref-type="supplementary-material"}). Lebers congential amaurosis, Leber hereditory optic neuritis, and choroideremia are the only conditions currently in phase 3 trials. Outcome measures were analyzed according to clinical trial phase and were separated into four categories: safety, validated tests, novel test methods, and non-specific ([**Supplementary Table**](#SM2){ref-type="supplementary-material"}).

Visual acuity was included in almost all studies as either a primary or a secondary measure. Various forms of perimetry also featured highly in the outcome measures list. Out of the 50 trials, 16 used broad descriptors which did not make clear what data were being collected or how it was going to be used. This included descriptors such as visual function or specifying imaging techniques with no details of the aspect of the images to be examined. One did not specify any outcome measures.

Published Trials {#s3_2}
----------------

One trial marked as completed has not yet been published (NCT00001735). Eighteen trials have associated results in the peer-reviewed literature. [**Table 1**](#T1){ref-type="table"} details the correlation between the trial register record and the outcomes reported in the peer-reviewed papers. Where primary and secondary outcomes were explicitly stated in the paper, these were recorded if also reported in the results. Anything not reported in the results or supplemental sections was not counted. In reports where primary or secondary was not made clear, all measures reported were recorded, and primary *versus* secondary was inferred from emphasis and context.

###### 

Comparison of clinical trial record and published outcomes in ocular gene therapy trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID (clinicaltrials.gov), disease and gene therapy delivery method             Phase; full/prelim   Pre-specified primary outcome                         Reported primary outcome                                                          Pre-specified secondary outcome                                                                                                                               Reported secondary outcome
  ----------------------------------------------------------------------------------- -------------------- ----------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT01024998\                                                                        I; full              Adverse events, maximum tolerated dose                Adverse events, change in VA and vector DNA concentration in biological samples   Decreased retinal thickness                                                                                                                                   Transgene expression in aqueous fluid and OCT thickness
  Neovascular AMD AAV intravitreal ([@B22])                                                                                                                                                                                                                                                                                                                                                                      

  NCT01494805\                                                                        I/II; both           Adverse events and laboratory measures                Adverse events and laboratory measures                                            VA, foveal thickness, and CNV lesion                                                                                                                          VA, retinal thickness, and standard injection retreatments
  Neovascular AMD AAV subretinal ([@B38]; [@B11])                                                                                                                                                                                                                                                                                                                                                                

  NCT01301443 Neovascular AMD lentivirus subretinal ([@B7])                           I; full              Adverse events                                        Adverse events, change in VA, ocular inflammation, IOP, laboratory measures       OCT intraretinal fluid                                                                                                                                        Transgene expression, OCT macular thickening, lesion measures on fluorescein angiography, VA

  NCT01461213\                                                                        I/II; prelim         VA                                                    VA                                                                                Microperimetry, OCT, and AF                                                                                                                                   Microperimetry threshold, OCT thickness, AF area
  Choroideremia AAV subretinal ([@B32]; [@B14])                                                                                                                                                                                                                                                                                                                                                                  

  NCT02553135\                                                                        II; full             Adverse events                                        VA, adverse events                                                                Macular autofluorescence, microperimetry                                                                                                                      Microperimetry, contrast sensitivity, color vision, autofluorescence area, OCT ellipsoid zone and choroidal thickness assessments, safety
  Choroideremia AAV subretinal ([@B30])                                                                                                                                                                                                                                                                                                                                                                          

  NCT02671539\                                                                        II; full             VA                                                    VA                                                                                Adverse events, autofluorescence, microperimetry, contrast sensitivity, color vision                                                                          Microperimetry, autofluorescence area, OCT ellipsoid zone and choroidal thickness, safety
  Choroideremia AAV subretinal ([@B16])                                                                                                                                                                                                                                                                                                                                                                          

  NCT02077361\                                                                        I/II; full           Adverse events                                        Safety including adverse events                                                   Microperimetry, Goldmann visual field, multifocal ERG, FST, OCT, photos, and autofluorescence                                                                 VA, autofluorescence area, OCT ellipsoid zone, microperimetry, quality of life questionnaire
  Choroideremia AAV subretinal ([@B13])                                                                                                                                                                                                                                                                                                                                                                          

  NCT01482195\                                                                        I; full              Adverse events and laboratory measures                Safety measures                                                                   VA and FST                                                                                                                                                    VA, FST, OCT thickness
  MERTK AAV subretinal ([@B18])                                                                                                                                                                                                                                                                                                                                                                                  

  NCT01267422\                                                                        Not given; prelim    VA, laboratory measures                               VA, laboratory measures                                                           IOP, neutralizing antibody assay, OCT RNFL thickness, computerized visual field mean deviation and visual field index, VEP, ERG, liver, and kidney function   Visual field index and mean deviation, VEP, OCT RNFL thickness, and blood tests
  LHON AAV intravitreal ([@B44])                                                                                                                                                                                                                                                                                                                                                                                 

  NCT02161380\                                                                        I; prelim            Toxicity                                              Loss of VA                                                                        None                                                                                                                                                          OCT RNFL thickness, pattern ERG, and adverse events
  LHON AAV intravitreal ([@B15])                                                                                                                                                                                                                                                                                                                                                                                 

  NCT01496040\                                                                        I/II; full           Biodistribution in urine and nasal samples            Adverse events and biodsitribution                                                ERG, questionnaire, distance VA, near VA, color vision, pupillometry, microperimetry, and dark adaptation                                                     Chorioretinal imaging, OCT thickness, undefined questionnaire, distance VA, nystagmus measures, visual field, microperimetry, fMRI, ERG, pupillometry, and mobility test
  LCA AAV subretinal (Le [@B36])                                                                                                                                                                                                                                                                                                                                                                                 

  NCT00749957\                                                                        I/II; full           Adverse events                                        Adverse events                                                                    Static perimetry and VA                                                                                                                                       VA, static perimetry hill of vision, kinetic perimetry hill of vision, ERG, OCT, photography, and quality of life questionnaire
  LCA AAV subretinal ([@B45])                                                                                                                                                                                                                                                                                                                                                                                    

  NCT00481546\                                                                        I; both              Toxicity, symptoms, and, adverse events               Laboratory measures, symptoms, and adverse events                                 Visual function                                                                                                                                               VA, FST, dark adaptation kinetics, chromatic stimuli sensitivity, kinetic perimetry, OCT thickness, fixation analysis, pupillary light reflex, mobility testing, eye movements, and fMRI
  LCA AAV subretinal ([@B21]; A. V. [@B8]; Artur V. [@B10]; [@B23]; Artur V. [@B9])                                                                                                                                                                                                                                                                                                                              

  NCT00516477\                                                                        I; both              Safety and tolerability                               Adverse events                                                                    Change in visual function psychophysical and objective measures                                                                                               Pupillary light reflex, nystagmus testing, kinetic perimetry, microperimetry, OCT, AF, FST, ERG, mobility testing, and fMRI
  LCA AAV subretinal ([@B33], [@B34]; [@B1]; [@B42])                                                                                                                                                                                                                                                                                                                                                             

  NCT01208389\                                                                        I/II; prelim         Adverse events                                        Adverse events                                                                    VA, VF, pupillary light response, mobility testing, FST, and contrast sensitivity                                                                             FST, kinetic perimetry, VA, pupillary light reflex, mobility, and fMRI
  LCA 2^nd^ eyes ([@B4])                                                                                                                                                                                                                                                                                                                                                                                         

  NCT00643747\                                                                        I/II; both           Inflammation                                          Adverse events                                                                    Visual function                                                                                                                                               Laboratory measures, VA, kinetic perimetry, microperimetry, dark-adapted perimetry, mobility, contrast sensitivity, color vision, spectral sensitivity, retinal imaging, and ERG
  LCA AAV subretinal (J W B [@B2]; James W.B. [@B3]; [@B39])                                                                                                                                                                                                                                                                                                                                                     

  NCT00999609\                                                                        3; full              Multi-luminance mobility testing bilateral            Multi-luminance mobility testing bilateral                                        FST, multi-luminance mobility testing monocular, and VA                                                                                                       FST, multi-luminance mobility testing monocular, VA, kinetic perimetry, Humphrey static visual fields, contrast sensitivity, and pupil light reflex
  LCA AAV subretinal ([@B40])                                                                                                                                                                                                                                                                                                                                                                                    

  NCT02317887\                                                                        1; full              Adverse events, retinal structure, ocular structure   Adverse events, inflammation                                                      Visual function, OCT, ERG, AAV antibodies                                                                                                                     VA, microperimetry, ERG, OCT macular thickness, AAV antibodies
  XLRS AAV intravitreal ([@B12])                                                                                                                                                                                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

References provided in brackets. AF, fundus autofluorescence; AMD, age-related macular degeneration; ERG, electroretinogram; FST, full-field stimulus threshold; IOP, intraocular pressure; OCT, ocular coherence tomography; RNFL, retinal nerve fiber layer; VA, visual acuity; VEP, visual evoked potential.

There was 100% compliance with reporting on the pre-specified primary outcome measures. Sixteen trials pre-specified one or more secondary outcome measure. These were met in full by 68% (11) trials. Five trials did not meet all of the outcome measures but did meet some of them. In addition, 83% (15/18) trials reported additional outcome measures, including a range of features, such as retinal imaging, aspects of visual function, and fMRI imaging. [**Figure 1A**](#f1){ref-type="fig"} demonstrates the number of additional secondary outcomes carried out in the published literature but not originally included in the register as a histogram. [**Figure 1B**](#f1){ref-type="fig"} shows the array of the visual function tests reported. VA was the most commonly used assessment of visual function. Perimetry was also commonly used but could take several different forms; each of which is targeting different areas of the visual field. Mobility testing is not standardized and appears in almost half the published trials. Electroretinograms are measured in a similar number of trials but are standardized due to ISCEV standards. The tests listed in low number of trials are generally non-standardized exploratory techniques such as fixation analysis and dark-adapted perimetry.

![**(A)** Histogram to show the number of additional outcome measures reported by 79% of trials with peer-reviewed publications. **(B)** Range of visual function tests currently used as secondary outcome measures in reported ocular gene therapy trials from [**Table 1**](#T1){ref-type="table"}.](fphar-10-01076-g001){#f1}

Discussion {#s4}
==========

Adverse events are a key part of phase 1 trials as would be expected. Visual acuity is also a frequent factor in determining treatment effects and is reported in 94% of trials. It is a widely accepted measure, both clinically and by medical regulatory authorities. VA has been reported to have higher variability in low vision patients so strategies to optimize VA measurements in patients with disease need to be better established ([@B27]).

Even within trials for the same disease, visual outcome measures used differ across sites, making direct comparison difficult. This is especially problematic due to the small numbers of patients involved in these highly specialized trials. The ideal way forward would be to conduct formal natural history studies and additional validation studies of novel outcome measures where existing measures are not sufficient or appropriate. The length of natural history studies should be determined by the nature of the disease being investigated. Fast progressing conditions will require a shorter follow-up period of 1 or 2 years. Slower progressive conditions should ideally have a longer follow-up period. An initial audit of imaging and functional data collected in the clinical environment can provide guidance on the speed of progression as a starting point such as conducted by [@B24] and [@B25] in choroideremia ([@B24], [@B25]). Combining structural and functional data will be helpful in better understanding the disease process as well as treatment impact in both natural history trials as well as in final outcome measures chosen.

Outcome measures should ideally be based on the biology of the disease and related to measurement of the therapeutic target within the eye, in order to maximize the chance of measuring a real therapeutic effect. This may change in end-stage disease *versus* trials designed for early disease states. The balance of structural *versus* functional measures is likely to change in late stage *versus* early stage disease. If the novel outcome measures are established in the disease prior to the interventional trials, the data can be submitted to the regulatory authorities in advance of the interventional trials. This would increase the acceptability of these measures. Outcome measures should be based on an understanding of the underlying disease process as well as the impact of the gene therapy as determined by the expected impact of the viral vector and cells likely to be transfected. A significant advantage of this approach would be the likelihood of reaching the final outcome more quickly due to the use of targeted and sensitive markers of disease.

Patient quality of life is highly dependent on their perception of the world. Subjective assessment using validated instruments can provide insights into visual perception from the patients' perspective and can be considered as part of the battery of outcome measures ([@B5]). Defining success based on clinical (such as repeatability) and patient (such as improvement required for greater quality of life) factors will make a stronger case for the success of therapy, particularly for phase 2 and 3 trials ([@B35]). Although questionnaire results may be considered biased due to the patients motivation, the subjective feedback can provide very powerful evidence for the real world impact of any therapy in a way that clinical measures are unable to achieve. Many funding bodies in the United Kingdom encourage the use of patient and participant involvement in research as the insights they can provide can have an influence on guiding researchers to improved clinical trial design, as well as impact when reporting results ([@B6]).

Despite visual function being highlighted as an important factor in the success of gene therapy trials, little progress has been made on developing a coherent approach worldwide ([@B43]). Other fields have highlighted similar issues for gene therapy ([@B29]). As more diseases are targeted by a gene therapy approach, and trials progress to phases 2 and 3, this will become ever more important. Cataract formation is a side effect of the invasive vector delivery techniques ([@B19]; [@B20]). Moreover, patients are followed up over long periods of time, increasing the chance of age-related cataract formation. Thus, it is necessary to account for the effect of cataract on visual function measures to ensure that any deficits do not interfere with determining the impact of gene therapy. Otherwise, results may be skewed in a negative way masking the therapeutic effect. Greater investment is needed in exploring disease parameters in more detail in order to complete gene therapy trials in an effective, timely, and cost-effective manner. This review provides an important starting point for clinical trial design.
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